AbbVie Valuation Overview

ABBV -- USA Stock  

USD 95.55  2.06  2.20%

AbbVie shows prevailing Real Value of $86.03175 per share. The current price of the firm is $95.55. At this time the firm appears to be over valued. Macroaxis approximates value of AbbVie from analyzing the firm fundamentals such as Profit Margin of 21.55% and Return On Equity of 149.25% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Valuation Drivers Correlation

Selected AbbVie Valuation Data Over Time

Net Income Per Employee    Average Assets    Enterprise Value    
 Time Horizon     30 Days    Login   to change
AbbVie is rated third in beta category among related companies. It is number one stock in price to book category among related companies fabricating about  26.98  of Price to Book per Beta.

Current Market Valuation

AbbVie Valuation Boundaries
Over Valued
June 24, 2018
95.55
Market Value
86.03
Real Value
Target Odds
  
108.08
Upside
AbbVie is not too risky asset. Calculation of real value of AbbVie is based on 1 month time horizon. Increasing AbbVie time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Tax Efficiency

AbbVie Tax Efficiency History

Tax Efficiency

Market Capitalization

AbbVie Market Capitalization Analysis
AbbVie is rated second in market capitalization category among related companies. Market capitalization of Pharmaceuticals And Biosciences industry is presently estimated at about 710.94 Billion. AbbVie totals roughly 149.1 Billion in market capitalization claiming about 21% of equities listed under Pharmaceuticals And Biosciences industry.
Capitalization  Valuation  Workforce  Total debt  Revenue
Check also Trending Equities. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.